Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) PT at $134.10

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $135.2033.

BNTX has been the subject of several analyst reports. Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the company an “overweight” rating in a report on Tuesday, August 5th. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Monday. Cowen reiterated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Bank of America dropped their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, October 22nd. Finally, Morgan Stanley restated an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a report on Monday, November 3rd.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Banque Cantonale Vaudoise purchased a new position in BioNTech in the 1st quarter worth $36,000. Financial Consulate Inc. purchased a new stake in BioNTech during the 3rd quarter valued at about $36,000. Huntington National Bank increased its holdings in shares of BioNTech by 1,266.7% in the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the period. LRI Investments LLC raised its stake in shares of BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after purchasing an additional 312 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after purchasing an additional 305 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Stock Performance

BNTX stock opened at $102.53 on Wednesday. BioNTech has a one year low of $81.20 and a one year high of $129.27. The firm has a market cap of $24.65 billion, a price-to-earnings ratio of -64.08 and a beta of 1.54. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The firm has a 50-day simple moving average of $102.92 and a two-hundred day simple moving average of $104.94.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of $0.75 by ($0.89). The firm had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company’s revenue was up 22.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.81 EPS. BioNTech has set its FY 2025 guidance at EPS. On average, equities analysts forecast that BioNTech will post -3.88 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.